Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mouwasat Medical Services CoSAU:4002 +0.77%100 Debt-to-EBITDA is 0.99 as of Jun. 2026, which is 6% below its 10-year median of 1.05. GuruFocus rates SAU:4002 with a GF Score™ of 100/100 and a GF Value™ of ﷼102.35 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 479 Healthcare Providers & Services companies, Mouwasat Medical Services Co ranks better than 69.52% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mouwasat Medical Services Co's Debt-to-EBITDA or its related term are showing as below:
SAU:4002'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.78 Med: 1.05 Max: 1.3
Current: 1.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of Mouwasat Medical Services Co was 1.30. The lowest was 0.78. And the median was 1.05.
SAU:4002's Debt-to-EBITDA is ranked better than 69.52% of 479
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs SAU:4002: 1.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mouwasat Medical Services Co Debt-to-EBITDA Related Terms
Mouwasat Medical Services Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAU:4002 vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Mouwasat Medical Services Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mouwasat Medical Services Co Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mouwasat Medical Services Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mouwasat Medical Services Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Mouwasat Medical Services Co (SAU:4002) has a Debt-to-EBITDA of 0.99 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mouwasat Medical Services Co. This is near median its historical median of 1.05. Over the past decade, Mouwasat Medical Services Co's Debt-to-EBITDA has ranged from 0.78 to 1.30. According to the industry distribution chart, Mouwasat Medical Services Co ranks #146 out of 479 companies in the Healthcare Providers & Services industry, placing it in the top 30.5%.
Is Mouwasat Medical Services Co's Debt-to-EBITDA too high?
Mouwasat Medical Services Co's current Debt-to-EBITDA of 0.99 is near median its 10-year median of 1.05. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 1.30. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Mouwasat Medical Services Co's value of 0.99 is 54.8% below this industry median. Based on the distribution chart, Mouwasat Medical Services Co ranks #146 out of 479 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Mouwasat Medical Services Co has a GF Score™ of 100/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mouwasat Medical Services Co's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Mouwasat Medical Services Co ranks #146 out of 479 companies for Debt-to-EBITDA. This puts Mouwasat Medical Services Co in the upper half of its industry. The industry median Debt-to-EBITDA is 2.19. Mouwasat Medical Services Co's value of 0.99 is 54.8% below this benchmark. Historically, Mouwasat Medical Services Co's own Debt-to-EBITDA has ranged from 0.78 to 1.30 over the past decade. While the company's 10-year median is 1.05 vs. the industry median of 2.19, Mouwasat Medical Services Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 479 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mouwasat Medical Services Co's current Debt-to-EBITDA of 0.99 is 54.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mouwasat Medical Services Co. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mouwasat Medical Services Co's current Debt-to-EBITDA is 0.99, which is near median its own 10-year median of 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mouwasat Medical Services Co stock overvalued right now?
Based on GuruFocus' analysis, Mouwasat Medical Services Co (SAU:4002) is currently considered Significantly Undervalued. The stock's GF Value™ is ﷼102.35, compared to a current price of ﷼65.35 — trading 36.2% below its estimated fair value. The current Debt-to-EBITDA is 0.99, which is near median its 10-year median of 1.05 and 54.8% below the Healthcare Providers & Services industry median of 2.19. Mouwasat Medical Services Co's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mouwasat Medical Services Co (SAU:4002), the current Debt-to-EBITDA is 0.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mouwasat Medical Services Co (SAU:4002) Overvalued in 2026?
Based on GuruFocus' analysis, Mouwasat Medical Services Co stock appears to be undervalued.
The current stock price of ﷼65.35 is trading 36.2% below its estimated GF Value™ of ﷼102.35.
GuruFocus considers Mouwasat Medical Services Co to be Significantly Undervalued.
Key valuation signals for SAU:4002:
Debt-to-EBITDA: 0.99 (near median its 10-year median of 1.05)
GF Value™: ﷼102.35 vs. price of ﷼65.35 (36.2% below fair value)
Industry Position: 54.8% below the Healthcare Providers & Services median (#146 of 479)
No single metric tells the full story. See the SAU:4002 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mouwasat Medical Services Co is engaged in the acquisition, management, operation, and maintenance of hospitals, medical centers, drug stores, pharmacies, and wholesale of medical equipment and drugs. The company also operates skin care centers that offer clinical and cosmetic dermatology, aesthetic and reconstructive plastic surgery, weight reduction, and esthetician services. It operates in two segments Medical Services segment and Pharmaceuticals out of which the Medical Services segment derives the majority of revenue. The Medical Services segment includes Inpatient and outpatient services. The company provides specialized centers: Eye Center, Robotic Surgeries Center, Diabetes Center, Fertility Unit, Cardiology Center, Stroke Unit, Long Term Care Center, Obesity Center, and others.
100GF Score
Get the complete analysis for SAU:4002
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4002 has been successfully added to your 
